PTK2B and neoplasm: MiR-517c showed a tumor suppressor activity in human glioblastoma (49) and hepatocellular carcinoma cells (50), respectively through the inhibition of the epithelial-to-mesenchymal-like transition phenotype by targeting KPNA2 mRNA and, thus, disrupting the TP53 nuclear translocation, and through the inhibition of cell proliferation by targeting PTK2B/Pyk2 mRNA.